Risk of squamous cell carcinoma in patients treated for basal cell carcinoma with Vismodegib or other therapies

Study identification

• EU PAS number:
  EUPAS21160
• Study ID:
  24704
• Official title and acronym:
  Risk of squamous cell carcinoma in patients treated for basal cell carcinoma with Vismodegib or other therapies
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  Comparison of pooled outcome data from patients treated with vismodegib as part of completed and ongoing phase I and II clinical studies with data from theUniversity of California, San Francisco (UCSF) Nonmelanoma Skin Cancer Cohort study of patients treated for primary basal cell carcinoma with standard therapy.Using these two cohorts, the aim was to determine whether treatment with vismodegib is associated with an increase in the risk of cutaneous SCC.
• Study status:
  Finalised

Research institutions and networks

Institutions

University of California, San Francisco

Study timelines

Date when funding contract was signed

Actual:09/12/2013

Study start date

Actual:01/01/2014

Date of final study report

Actual:28/03/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Genentech, Inc./Hoffmann-La Roche

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

GO39138